TOPLINE:

In high-risk patients with COVID-19, nirmatrelvir/ritonavir treatment shortened the median duration to return to usual health and activities and significantly accelerated the resolution of COVID-19 symptoms while providing sustained relief from these symptoms compared with placebo.

METHODOLOGY:

Researchers analyzed patient-reported outcomes to assess how nirmatrelvir treatment affects symptom burden, work productivity, and health-related quality of life after COVID-19 diagnosis.

Overall, 2091 nonhospitalized, high-risk patients with COVID-19 (median age, 45 years; 50.4% men) were randomly assigned to receive either nirmatrelvir/ritonavir (300 mg/100 mg) or a placebo twice daily for 5 days.

Patients provided daily responses through day 28 to the Global Impression Questions reg

See Full Page